Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation—evaluating N-acetylcysteine treatment (ACCENT) study

American Journal on Addictions

Volumn 26, Issue 2, 2017, Pages 136-144

  Sherman, Brian J ^a   McRae Clark, Aimee L ^a   Baker, Nathaniel L ^a   Sonne, Susan C ^a   Killeen, Therese K ^a   Cloud, Kasie ^b   Gray, Kevin M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b CODA Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; PLACEBO; CANNABINOID; SCAVENGER;

ADULT; AGORAPHOBIA; ARTICLE; CANNABIS ADDICTION; CHRONIC PAIN; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CRAVING; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; PANIC; POOR GENERAL CONDITION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT PLANNING; WITHDRAWAL SYNDROME; CLINICAL TRIAL; COMORBIDITY; MENTAL DISEASE; MIDDLE AGED; MULTICENTER STUDY; PATIENT ATTITUDE; PATIENT CARE; PROCEDURES; PSYCHOLOGY;

ACETYLCYSTEINE; ADULT; CANNABINOIDS; COMORBIDITY; FEMALE; FREE RADICAL SCAVENGERS; HELP-SEEKING BEHAVIOR; HUMANS; MALE; MARIJUANA ABUSE; MENTAL DISORDERS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT CARE MANAGEMENT; SEX FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 85011649763     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12503     Document Type: Article

References (39)

1. SAMHSA. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. HHS Publication No. SMA 15-4927, NSDUH Series H-50. 2015.
2. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009; 374:1383–1391.
3. Lopez-Quintero C, de los Cobos JP, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: Results of the national epidemiologic survey on alcohol and related conditions (nesarc). Drug Alcohol Depend. 2011; 115:120–130.
4. Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl J Med. 2014; 370:2219–2227.
5. SAMHSA. Treatment Episode Data Set (TEDS):2003–2013. National Admissions to Substance Abuse Treatment Services. Vol BHSIS Series S-75, HHS Publication No. (SMA) 15–4934. RockvilleMD: Substance Abuse and Mental Health Services Administration; 2014.
6. Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004; 74:265–272.
7. Khan SS, Secades-Villa R, Okuda M, et al. Gender differences in cannabis use disorders: Results from the National Epidemiologic Survey of Alcohol and Related Conditions. Drug Alcohol Depend. 2013; 130:101–108.
8. Cooper ZD, Haney M. Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend. 2014; 136:85–91.
9. Copersino ML, Boyd SJ, Tashkin DP, et al. Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal. Am J Drug Alcohol Abuse. 2010; 36:311–319.
10. Herrmann ES, Weerts EM, Vandrey R. Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. Exp Clin Psychopharmacol. 2015; 23:415–421.
11. Davis JP, Smith DC, Morphew JW, et al. Cannabis withdrawal, posttreatment abstinence, and days to first cannabis use among emerging adults in substance use treatment: A prospective study. J Drug Issues. 2016; 46:64–83.
12. Lev-Ran S, Imtiaz S, Taylor BJ, et al. Gender differences in health-related quality of life among cannabis users: Results from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend. 2012; 123:190–200.
13. Fattore L, Fadda P, Fratta W. Sex differences in the self-administration of cannabinoids and other drugs of abuse. Psychoneuroendocrinology. 2009; 34:S227–S236.
14. Harte-Hargrove LC, Dow-Edwards DL. Withdrawal from THC during adolescence: Sex differences in locomotor activity and anxiety. Behav Brain Res. 2012; 231:48–59.
15. Sherman BJ, McRae-Clark AL. Treatment of cannabis use disorder: Current science and future outlook. Pharmacotherapy. 2016; 36:511–535.
16. Copeland J, Swift W, Rees V. Clinical profile of participants in a brief intervention program for cannabis use disorder. J Subst Abuse Treat. 2001; 20:45–52.
17. Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: A test of the relapse prevention model. J Consult Clin Psychol. 1994; 62:92–99.
18. McRae-Clark AL, Baker NL, Gray KM, et al. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 2015; 156:29–37.
19. McClure EA, Sonne SC, Winhusen T, et al. Achieving cannabis cessation—evaluating N-acetylcysteine treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials. 2014; 39:211–223.
20. Sobell LC, Sobell MB, Leo GI, et al. Reliability of a timeline method: Assessing normal drinkers’ reports of recent drinking and a comparative evaluation across several populations. Br J Addict. 1988; 83:393–402.
21. Mariani JJ, Brooks D, Haney M, et al. Quantification and comparison of marijuana smoking practices: Blunts, joints, and pipes. Drug Alcohol Depend. 2011; 113:249–251.
22. Allsop DJ, Norberg MM, Copeland J, et al. The cannabis withdrawal scale development: Patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend. 2011; 119:123–129.
23. Heishman SJ, Evans RJ, Singleton EG, et al. Reliability and validity of a short form of the marijuana craving questionnaire. Drug Alcohol Depend. 2009; 102:35–40.
24. Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol. 2000; 68:898–908.
25. Franken IH, Hendriksa VM, van den Brink W. Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addict Behav. 2002; 27:675–685.
26. First MS, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV-TR Axis I disorders, research version, patient edition. SCIP-I/P. New York: Biometrics Research, New York State Psychiatric Institute; 1994.
27. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The mini-international neuropsychiatric interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59:34–57.
28. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica. 1983; 67:361–370.
29. Heatherton TF, Kozlowski LT, Frecker RC. The Fagerstrom test for nicotine dependence: A revision of the Fagerstrom tolerance questionnaire. Br J Addict. 1991; 86:1119–1127.
30. Feise RJ. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol. 2002; 2:8.
31. Schulz KF, Grimes DA. Multiplicity in randomized trials I: Endpoints and treatments. Lancet. 2005; 365:1591–1595.
32. Sidak ZK. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc. 1967; 62:626–633.
33. Buckner JD, Carroll KM. Effect of anxiety on treatment presentation and outcome: Results from the Marijuana Treatment Project. Psychiatry Res. 2010; 178:493–500.
34. Sherman BJ, Baker NL, McRae-Clark AL. Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women. Addict Behav. 2016; 60:197–202.
35. Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology. 2013; 38:1984–1992.
36. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. Can Med Assoc J. 2010; 182:E694–E701.
37. Wilsey B, Marcotte T, Deutsch R, et al. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013; 14:136–148.
38. de Dios MA, Herman DS, Britton WB, et al. Motivational and mindfulness intervention for young adult female marijuana users. J Subst Abuse Treat. 2012; 42:56–64.
39. Herrmann ES, Cooper ZD, Bedi G, et al. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology (Berl). 2016; 233:2469–2478.